Atrial Natriuretic Peptide (ANP), Rat: Precision Tool for Vasodilator and Blood Pressure Regulation Research

Executive Summary: Atrial Natriuretic Peptide (ANP), rat, is a 28-amino-acid peptide hormone with the sequence H-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-OH and a molecular weight of 1225.38 g/mol, validated by HPLC and mass spectrometry to ≥95.92% purity (APExBIO). It is synthesized in atrial myocytes and secreted in response to stretch, angiotensin II, endothelin, and sympathetic stimuli, acting as a potent vasodilator and natriuretic agent (see related review). ANP modulates water, sodium, and adipose tissue homeostasis, contributing to blood pressure regulation. Its effects are dose-dependent and species-specific, making it indispensable for cardiovascular and renal research (APExBIO). Recent literature also links ANP signaling to neuroimmune and metabolic pathways (Zhang et al., 2022).

Biological Rationale

Atrial Natriuretic Peptide (ANP), rat, is a member of the natriuretic peptide family. It is synthesized, stored, and released by atrial myocytes in response to increased atrial wall tension and neurohumoral stimuli such as angiotensin II and endothelin. Its primary function is to induce natriuresis, diuresis, and vasodilation, thereby reducing blood volume and systemic vascular resistance (see mechanistic perspective). ANP also influences adipose tissue metabolism by modulating lipolysis and adipokine secretion. It acts as a counter-regulatory hormone to the renin-angiotensin-aldosterone system (RAAS), playing a central role in cardiovascular homeostasis.

Mechanism of Action of Atrial Natriuretic Peptide (ANP), rat

Upon release, ANP binds to membrane-bound guanylyl cyclase-A (GC-A) receptors, leading to increased intracellular cyclic GMP (cGMP) levels. This signaling cascade induces smooth muscle relaxation, resulting in vasodilation and decreased systemic blood pressure. In the kidney, ANP increases glomerular filtration rate (GFR), inhibits sodium reabsorption in the distal nephron, and suppresses renin and aldosterone secretion. ANP also modulates adipocyte metabolism and has emerging roles in neuroimmune regulation, as supported by cross-talk with the TLR4/NF-κB pathway in recent rodent studies (Zhang et al., 2022).

Evidence & Benchmarks

• ANP, rat, reduces systolic blood pressure by 10–20 mmHg in normotensive rats at 0.1–1 μg/kg intravenous dosing (see APExBIO product data).
• Purity of the APExBIO A1009 ANP, rat, peptide is confirmed at 95.92% by HPLC and mass spectrometry under standard conditions (see specification sheet).
• In vitro, ANP exerts potent vasodilatory effects in isolated rat aortic rings with EC50 values in the nanomolar range (see competitive benchmarks).
• ANP induces natriuresis and diuresis in Sprague-Dawley rats, with sodium excretion increasing by 30–50% within 2 hours post-injection (see mechanistic review).
• ANP modulates adipose tissue metabolism by enhancing lipolysis and regulating adiponectin secretion, with implications for metabolic and neuroinflammatory pathways (Zhang et al., 2022).

Applications, Limits & Misconceptions

ANP, rat, is widely employed in preclinical models to study blood pressure regulation, natriuresis, and cardiovascular disease mechanisms. It is also used in research on renal physiology, adipose tissue metabolism, and neuroimmune signaling. The APExBIO A1009 peptide is formulated for high solubility in DMSO (≥122.5 mg/mL) and water (≥43.5 mg/mL), but is insoluble in ethanol. This ensures compatibility with most in vitro and in vivo protocols. For extended discussions on translational and mechanistic applications, see this review, which this article updates by incorporating new evidence on neuroimmune signaling and metabolic cross-talk.

Common Pitfalls or Misconceptions

• ANP, rat, is not effective for chronic hypertension models without repeated dosing; its effects are acute and transient.
• The peptide is species-specific; human ANP analogs may exhibit different kinetics and efficacy in non-rodent models.
• ANP is unstable in solution at room temperature; solutions should be freshly prepared and not stored long-term.
• ANP does not directly inhibit TLR4/NF-κB signaling; observed neuroimmune effects are mediated indirectly.
• It is ineffective when dissolved in ethanol due to insolubility; only DMSO or water should be used for stock solutions.

Workflow Integration & Parameters

APExBIO's Atrial Natriuretic Peptide (ANP), rat, SKU A1009, is supplied as a solid, stable at -20°C. For experimental use, dissolve in DMSO (≥122.5 mg/mL) or water (≥43.5 mg/mL). Avoid ethanol as a solvent. Use freshly prepared solutions to maintain peptide integrity. The peptide is suitable for cell-based assays, animal infusions, and biochemical quantification. For troubleshooting and advanced protocol integration, this article offers detailed workflow solutions; the current review extends these by providing updated purity data and cross-pathway considerations.

Conclusion & Outlook

Atrial Natriuretic Peptide (ANP), rat (A1009), from APExBIO is a rigorously validated reagent for cardiovascular, renal, and metabolic research. Its high purity and well-characterized mechanism of action enable robust modeling of vasodilatory and natriuretic processes. Recent studies extend its relevance to neuroimmune and metabolic pathways, underscoring its utility in next-generation translational research. For further reading on integrated neurocardiometabolic applications, see this article, which is complemented and updated by the present review's focus on experimental validation and workflow integration.

To order or learn more, visit the Atrial Natriuretic Peptide (ANP), rat product page.